ZelosDx is a pioneering brand dedicated to addressing the global impact of neurodegenerative diseases. With over 35 million patients worldwide affected by these conditions, ZelosDx is at the forefront of developing innovative solutions. They have developed a proprietary clinical research assay that detects brain biomarkers, enabling breakthrough discoveries in brain health and disease.

Neurologic diseases and brain trauma impact the lives of over 100 million patients in the US alone, resulting in significant healthcare costs. ZelosDx recognizes the urgent need for accessible and cost-effective blood testing products to aid in research and drug development. By leveraging a unique discovery, ZelosDx has identified a source of brain-derived biomarkers in peripheral blood monocytes.

These biomarkers indicate recent neurological damage and can be obtained through a simple blood sample. Essentially, ZelosDx's blood testing products serve as a non-invasive brain biopsy, providing crucial insights into pathological changes and aiding in timely diagnoses. ZelosDx has also been recognized for their groundbreaking work, recently receiving a Small Business Innovation Research (SBIR) Phase l Award from the National Science Foundation (NSF) for their project focused on the diagnostic potential of phagocytic cells in peripheral blood.

Discover the future of neurodegenerative disease detection with ZelosDx